Cost-effectiveness Analysis of Whole Brain Radiation(WBRT) Alone, Stereotactic Radiosurgery (SRS) Alone or the Combination of WBRT and SRS for Brain Metastases

2009 ◽  
Vol 75 (3) ◽  
pp. S495
Author(s):  
D.S. Higginson ◽  
J.L. Hubbs ◽  
D.E. Morris
Keyword(s):  
Cost Effectiveness ◽  
Brain Metastases ◽  
Stereotactic Radiosurgery ◽  
Cost Effectiveness Analysis ◽  
Whole Brain ◽  
Whole Brain Radiation ◽  
Effectiveness Analysis ◽  
Brain Radiation

scholarly journals Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases

2016 ◽  
Vol 125 (Supplement_1) ◽  
pp. 18-25 ◽  
Author(s):  
Nataniel H. Lester-Coll ◽  
Arie P. Dosoretz ◽  
William J. Magnuson ◽  
Maxwell S. Laurans ◽  
Veronica L. Chiang ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cost Effectiveness ◽  
Brain Metastases ◽  
Stereotactic Radiosurgery ◽  
Cost Effective ◽  
Sensitivity Analyses ◽  
Whole Brain ◽  
Whole Brain Radiation ◽  
The Cost ◽  
Brain Radiation

OBJECTIVEThe JLGK0901 study found that stereotactic radiosurgery (SRS) is a safe and effective treatment option for treating up to 10 brain metastases. The purpose of this study is to determine the cost-effectiveness of treating up to 10 brain metastases with SRS, whole-brain radiation therapy (WBRT), or SRS and immediate WBRT (SRS+WBRT).METHODSA Markov model was developed to evaluate the cost effectiveness of SRS, WBRT, and SRS+WBRT in patients with 1 or 2–10 brain metastases. Transition probabilities were derived from the JLGK0901 study and modified according to the recurrence rates observed in the Radiation Therapy Oncology Group (RTOG) 9508 and European Organization for Research and Treatment of Cancer (EORTC) 22952–26001 studies to simulate the outcomes for patients who receive WBRT. Costs are based on 2015 Medicare reimbursements. Health state utilities were prospectively collected using the Standard Gamble method. End points included cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). The willingness-to-pay (WTP) threshold was $100,000 per QALY. One-way and probabilistic sensitivity analyses explored uncertainty with regard to the model assumptions.RESULTSIn patients with 1 brain metastasis, the ICERs for SRS versus WBRT, SRS versus SRS+WBRT, and SRS+WBRT versus WBRT were $117,418, $51,348, and $746,997 per QALY gained, respectively. In patients with 2–10 brain metastases, the ICERs were $123,256, $58,903, and $821,042 per QALY gained, respectively. On the sensitivity analyses, the model was sensitive to the cost of SRS and the utilities associated with stable post-SRS and post-WBRT states. In patients with 2–10 brain metastases, SRS versus WBRT becomes cost-effective if the cost of SRS is reduced by $3512. SRS versus WBRT was also cost effective at a WTP of $200,000 per QALY on the probabilistic sensitivity analysis.CONCLUSIONSThe most cost-effective strategy for patients with up to 10 brain metastases is SRS alone relative to SRS+WBRT. SRS alone may also be cost-effective relative to WBRT alone, but this depends on WTP, the cost of SRS, and patient preferences.

Sign in / Sign up

Export Citation Format

Share Document